Kang Choon Lee
Dr. Kang Choon Lee is Haengdan Distinguished Professor at the SungKyunKwan University (SKKU), Korea, and was director of the Center of Excellence for Future Pharmaceutical Education and Research in the College of Pharmacy at SKKU. He served as a professor and dean at the College of Pharmacy as well as the director of the Institute of Pharmaceutical Science. Prior to joining SKKU in 1992, Dr. Lee was a principal scientist at Dong-A Pharmaceutical Co. for ten years before joining Chonnam National University as a professor of pharmacy. For over 30 years, Dr. Lee’s Drug Targeting Laboratory has been focused on immuno-targeting including immunotoxins, preformulation and bioconjugation of peptide and protein drugs. Dr. Lee is internationally recognized as one of the leading experts in site-specific peptide/protein PEGylation and firstly demonstrated the therapeutic potential of novel site-specific PEGylated drugs such as GLP-1 and TRAIL. He has published over 150 papers in peer-reviewed journals and served as an invited speaker at many international conferences. Dr. Lee is an inventor on more than 20 patents related to specific bioconjugation and modification of peptide/protein drugs. He served as president of the Korean-American Pharmaceutical Scientists Association and vice-president of the Pharmaceutical Society of Korea and Korean Society of Pharmaceutical Science and Technology. Dr. Lee is a recipient of the Distinguished Pharmaceutical Scientist Award from the Pharmaceutical Society of Korea in 2002 and honored as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2003. He currently serves on the editorial advisory board of many international scientific journals including Pharmaceutical Research, Pharmaceutical Development and Technology, PharmSciTech, Journal of Drug Delivery and Heliyon. For clinically translating and commercializing of site-specific PEGylated peptide/protein drugs developed by his laboratory, he co-founded B&L DeliPharm, Korea and Theraly Pharmaceuticals, USA.
on immuno-targeting including immunotoxins, preformulation and bioconjugation of peptide and protein drugs